M2RLAB 001

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameM2RLAB 001

Drug Alias NameAutologous Leukocyte Cells therapy (M2RLAB SL)M2RLAB 001

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy

Mechanisms of ActionLeukocytes modulators

TargetsNot applicable

Therapy Area/IndicationsAcute Kidney Injury

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesM2rlab SL

China Registration ClassN/A

Develop Information

Active CompaniesM2rlab SL

Inactive CompaniesN/A

Active IndicationsAcute Kidney Injury

Inactive IndicationsN/A

Other Information

ATC CodeN/A